Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.58 |
| ▸ | PRCP | P42785 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | GALR3 | O60755 | 1/20 | 0.48 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | PLK1 | P53350 | 4/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | KRAS | P01116 | 1/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4375461 | 1.00 | HTR7 (0.58) | HTR7PRCPMAP4K4GALR3NR2F2 | |
| SCHEMBL4375466 | 1.00 | HTR7 (0.58) | HTR7PRCPMAP4K4GALR3NR2F2 | |
| SCHEMBL17560828 | 0.88 | HTR7 (0.70) | HTR7PRCPMAP4K4GALR3NR2F2 | |
| SCHEMBL20575147 | 0.84 | HTR7 (0.53) | HTR7PRCPJAK2JAK3EGFR | |
| SCHEMBL20575148 | 0.84 | HTR7 (0.53) | HTR7PRCPJAK2JAK3EGFR | |
| SCHEMBL23780468 | 0.84 | PRCP (0.45) | HTR7PRCPJAK2JAK3PLK1 | |
| SCHEMBL10964333 | 0.82 | HTR7 (0.59) | HTR7PRCPMAP4K4GALR3NR2F2 | |
| SCHEMBL23291891 | 0.81 | EGFR (0.45) | HTR7PRCPJAK2JAK3PLK1 | |
| SCHEMBL30047569 | 0.81 | HTR7 (0.58) | HTR7PRCPMAP4K4GALR3NR2F2 | |
| SCHEMBL7854982 | 0.78 | HTR7 (0.56) | HTR7PRCPMAP4K4GALR3NR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807273-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-08-03 | — | — | EP | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | HTR7 1771/4885PRCP 2233/4885MAP4K4 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.